# Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

> **NCT00072085** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant

## Key facts

- **NCT ID:** NCT00072085
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072085, "Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00072085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*